# BioLattice Ophthalmics, Inc,: Form D capital raise (Philadelphia, PA)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 69/100
**Estimated post-raise budget for this service type:** $36,500 (heuristic)

| Field | Value |
|---|---|
| Industry | Biotechnology (Healthcare & Life Sciences) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $1,825,000 |
| Total offering | $3,310,000 |
| Investors so far | 7 |
| First sale | 2026-03-06 |
| Filed | 2026-10-28 (amendment) |
| Entity | Corporation, incorporated 2023 |

## Executives and related persons (as listed in the filing)
- Linda Alunkal: Executive Officer, Director
- Amelia Zellander: Executive Officer, Director
- Gregory Jackson: Director

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $1,825,000 so far.
- Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
- Filed 7 days ago.
- Incorporated in the last five years: likely still building out finance and insurance.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/2125596/000212559626000003/). Last refreshed: 2026-11-04T01:28:40.459Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.